Novo Nordisk A/S (NVO) Financials

$68.64 -1.80 (-2.56%)

Closing price 03:59 PM Eastern

Extended Trading

$68.91 +0.27 (+0.39%)

As of 06:41 PM Eastern

Annual Income Statements for Novo Nordisk A/S

This table shows Novo Nordisk A/S's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Net Income / (Loss) Attributable to Common Shareholders	14,017	12,418	7,988	7,269	6,926	5,853
Consolidated Net Income / (Loss)	14,017	12,418	7,988	7,269	6,926	5,853
Net Income / (Loss) Continuing Operations	14,017	12,418	7,988	7,269	6,926	5,853
Total Pre-Tax Income	17,654	15,533	9,935	8,992	8,733	7,295
Total Operating Income	17,813	15,221	10,762	8,925	8,897	7,886
Total Gross Profit	34,128	29,159	21,363	17,829	17,425	15,316
Total Revenue	40,308	34,466	25,456	21,429	20,866	18,344
Operating Revenue	40,308	34,466	25,456	21,429	20,866	18,344
Total Cost of Revenue	6,180	5,307	4,092	3,601	3,441	3,619
Operating Cost of Revenue	6,180	5,307	4,092	3,601	3,441	3,619
Total Operating Expenses	16,315	13,937	10,602	8,903	8,529	7,430
Selling, General & Admin Expense	9,352	9,141	7,291	6,249	6,063	5,384
Research & Development Expense	6,671	4,814	3,459	2,705	2,541	2,137
Other Operating Expenses / (Income)	292	-18	-149	-51	-76	-90
Total Other Income / (Expense), net	-159	312	-827	66	-164	0.00
Interest Expense	1,020	125	861	373	431	-
Interest & Investment Income	860	437	34	439	268	-
Income Tax Expense	3,637	3,115	1,947	1,723	1,807	1,443
Basic Earnings per Share	$3.15	$2.77	$1.76	$10.40	$18.05	$16.41
Weighted Average Basic Shares Outstanding	4.47B	4.51B	2280T	2.31B	-	-
Diluted Earnings per Share	$3.14	$2.76	$1.76	$10.37	$18.01	$16.38
Weighted Average Diluted Shares Outstanding	4.47B	4.51B	2280T	2.31B	-	-
Weighted Average Basic & Diluted Shares Outstanding	4.47B	4.51B	2280T	2.31B	-	-

No quarterly income statements for Novo Nordisk A/S are available.

This table details how cash moves in and out of Novo Nordisk A/S's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Net Change in Cash & Equivalents	5,321	5,014	312	1,562	-449	1,695
Net Cash From Operating Activities	22,000	18,216	11,348	9,189	8,539	8,369
Net Cash From Continuing Operating Activities	16,790	18,216	11,309	9,189	8,523	8,369
Net Income / (Loss) Continuing Operations	14,017	12,418	7,988	7,269	6,926	5,853
Consolidated Net Income / (Loss)	14,017	12,418	7,988	7,269	6,926	5,853
Depreciation Expense	2,652	1,397	1,059	917	946	851
Non-Cash Adjustments To Reconcile Net Income	3,358	3,272	4,389	659	720	732
Changes in Operating Assets and Liabilities, net	1,972	1,129	-2,127	344	-69	934
Net Cash From Investing Activities	-17,891	-3,829	-3,585	-3,747	-3,688	-1,341
Net Cash From Continuing Investing Activities	-17,891	-3,829	-3,140	-3,747	-3,628	-1,341
Purchase of Property, Plant & Equipment	-6,546	-3,829	-375	-964	-2,672	-1,342
Acquisitions	-11,404	0.00	-1,018	-2,783	0.00	0.00
Net Cash From Financing Activities	1,212	-9,372	-7,451	-3,880	-5,300	-5,332
Net Cash From Continuing Financing Activities	1,212	-9,372	-7,451	-3,880	-5,300	-5,332
Repayment of Debt	-879	-218	-1,960	-1,018	-156	-124
Repurchase of Common Equity	-2,801	-4,441	-3,465	-2,960	-2,770	-2,304
Payment of Dividends	-6,127	-4,714	-3,640	-3,275	-3,307	-2,916
Issuance of Debt	11,019	0.00	1,613	3,373	934	12
Cash Interest Paid	85	73	-	40	-	31
Cash Interest Received	261	159	40	37	16	9.62
Cash Income Taxes Paid	4,113	3,843	-	2,197	-	-

No quarterly cash flow statements for Novo Nordisk A/S are available.

This table presents Novo Nordisk A/S's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Total Assets	64,652	46,668	34,706	29,604	23,821
Total Current Assets	22,333	20,723	15,564	13,027	10,817
Short-Term Investments	878	348	392	257	383
Accounts Receivable	9,987	9,612	7,273	6,186	4,559
Inventories, net	5,670	4,721	3,508	2,986	3,047
Prepaid Expenses	1,751	1,197	864	767	-
Current Deferred & Refundable Income Taxes	396	360	135	170	48
Plant, Property, & Equipment, net	0.00	0.00	9,591	8,426	8,263
Total Noncurrent Assets	19,154	12,174	9,474	8,030	4,535
Intangible Assets	15,419	8,964	7,328	6,571	3,395
Noncurrent Deferred & Refundable Income Taxes	3,418	3,024	2,000	1,320	964
Other Noncurrent Operating Assets	316	-	146	139	175
Total Liabilities & Shareholders' Equity	64,652	46,668	34,706	29,604	23,821
Total Liabilities	44,737	30,855	22,696	18,836	13,412
Total Current Liabilities	30,193	25,176	17,398	15,146	11,551
Short-Term Debt	2,865	1,150	629	2,415	1,450
Accounts Payable	4,004	3,800	2,242	1,350	940
Current Deferred & Payable Income Tax Liabilities	1,349	1,056	1,020	557	643
Other Current Liabilities	21,975	19,170	13,507	10,824	8,517
Total Noncurrent Liabilities	14,544	5,679	5,298	3,690	1,861
Long-Term Debt	12,447	3,046	3,498	1,973	476
Noncurrent Deferred & Payable Income Tax Liabilities	753	1,508	1,016	802	411
Noncurrent Employee Benefit Liabilities	125	110	110	195	230
Other Noncurrent Operating Liabilities	1,218	1,015	675	721	744
Total Equity & Noncontrolling Interests	19,916	15,813	12,010	10,767	10,409
Total Preferred & Common Equity	19,916	15,813	12,010	10,767	10,708
Total Common Equity	19,916	15,813	12,010	10,767	10,708
Common Stock	62	67	66	70	77
Retained Earnings	20,049	15,558	11,593	10,959	10,482
Treasury Stock	-0.28	-0.74	-0.86	-0.91	-1.31
Other Equity Adjustments	-195	189	352	-261	150

This table presents Novo Nordisk A/S's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q4 2023	Q4 2022	Q4 2021	Q4 2020
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Total Assets	64,652	46,668	34,706	29,604	23,821
Total Current Assets	22,333	20,723	15,564	13,027	10,817
Short-Term Investments	878	348	392	257	383
Accounts Receivable	9,987	9,612	7,273	6,186	4,559
Inventories, net	5,670	4,721	3,508	2,986	3,047
Prepaid Expenses	1,751	1,197	864	767	-
Current Deferred & Refundable Income Taxes	396	360	135	170	48
Plant, Property, & Equipment, net	0.00	0.00	9,591	8,426	8,263
Total Noncurrent Assets	19,154	12,174	9,474	8,030	4,535
Intangible Assets	15,419	8,964	7,328	6,571	3,395
Noncurrent Deferred & Refundable Income Taxes	3,418	3,024	2,000	1,320	964
Other Noncurrent Operating Assets	316	-	146	139	175
Total Liabilities & Shareholders' Equity	64,652	46,668	34,706	29,604	23,821
Total Liabilities	44,737	30,855	22,696	18,836	13,412
Total Current Liabilities	30,193	25,176	17,398	15,146	11,551
Short-Term Debt	2,865	1,150	629	2,415	1,450
Accounts Payable	4,004	3,800	2,242	1,350	940
Current Deferred & Payable Income Tax Liabilities	1,349	1,056	1,020	557	643
Other Current Liabilities	21,975	19,170	13,507	10,824	8,517
Total Noncurrent Liabilities	14,544	5,679	5,298	3,690	1,861
Long-Term Debt	12,447	3,046	3,498	1,973	476
Noncurrent Deferred & Payable Income Tax Liabilities	753	1,508	1,016	802	411
Noncurrent Employee Benefit Liabilities	125	110	110	195	230
Other Noncurrent Operating Liabilities	1,218	1,015	675	721	744
Total Equity & Noncontrolling Interests	19,916	15,813	12,010	10,767	10,409
Total Preferred & Common Equity	19,916	15,813	12,010	10,767	10,708
Total Common Equity	19,916	15,813	12,010	10,767	10,708
Common Stock	62	67	66	70	77
Retained Earnings	20,049	15,558	11,593	10,959	10,482
Treasury Stock	-0.28	-0.74	-0.86	-0.91	-1.31
Other Equity Adjustments	-195	189	352	-261	150

This table displays calculated financial ratios and metrics derived from Novo Nordisk A/S's official financial filings.

Metric	2024	2023	2022	2021	2020	2019
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Growth Metrics	-	-	-	-	-	-
Revenue Growth	16.95%	35.40%	18.79%	2.70%	13.75%	0.00%
EBITDA Growth	23.15%	40.58%	20.10%	0.00%	12.66%	0.00%
EBIT Growth	17.03%	41.44%	20.57%	0.32%	12.82%	0.00%
NOPAT Growth	16.23%	40.64%	19.92%	2.25%	11.53%	0.00%
Net Income Growth	12.88%	55.47%	9.89%	4.94%	18.34%	0.00%
EPS Growth	13.68%	57.18%	9.89%	4.94%	9.95%	0.00%
Operating Cash Flow Growth	20.77%	60.52%	23.50%	7.61%	2.04%	0.00%
Free Cash Flow Firm Growth	-66.29%	173.52%	108.99%	312.89%	0.00%	0.00%
Invested Capital Growth	518.17%	-90.07%	1.32%	35.15%	0.00%	0.00%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profitability Metrics	-	-	-	-	-	-
Gross Margin	84.67%	84.60%	83.92%	83.20%	83.51%	83.49%
EBITDA Margin	50.77%	48.22%	46.44%	45.93%	47.17%	47.63%
Operating Margin	44.19%	44.16%	42.28%	41.65%	42.64%	42.99%
EBIT Margin	44.19%	44.16%	42.28%	41.65%	42.64%	42.99%
Profit (Net Income) Margin	34.78%	36.03%	31.38%	33.92%	33.19%	31.90%
Tax Burden Percent	79.40%	79.95%	80.40%	80.83%	79.31%	80.22%
Interest Burden Percent	99.11%	102.05%	92.32%	100.74%	98.16%	92.51%
Effective Tax Rate	20.60%	20.05%	19.60%	19.17%	20.69%	19.78%
Return on Invested Capital (ROIC)	323.26%	180.35%	70.94%	68.45%	157.42%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	324.20%	176.87%	-11.36%	-44.24%	175.40%	0.00%
Return on Net Nonoperating Assets (RNNOA)	-244.80%	-91.08%	-0.81%	0.20%	-24.33%	0.00%
Return on Equity (ROE)	78.46%	89.26%	70.14%	68.65%	133.08%	0.00%
Cash Return on Invested Capital (CROIC)	178.96%	344.23%	69.63%	38.55%	-42.58%	0.00%
Operating Return on Assets (OROA)	32.00%	37.41%	33.47%	33.41%	37.35%	0.00%
Return on Assets (ROA)	25.18%	30.52%	24.84%	27.21%	29.08%	0.00%
Return on Common Equity (ROCE)	78.46%	89.26%	70.14%	69.62%	136.91%	0.00%
Return on Equity Simple (ROE_SIMPLE)	70.38%	78.53%	66.51%	67.50%	64.68%	0.00%
Net Operating Profit after Tax (NOPAT)	14,144	12,169	8,652	7,215	7,056	6,326
NOPAT Margin	35.09%	35.31%	33.99%	33.67%	33.82%	34.49%
Net Nonoperating Expense Percent (NNEP)	-0.94%	3.48%	82.30%	112.69%	-17.98%	0.00%
Return On Investment Capital (ROIC_SIMPLE)	40.15%	60.82%	53.62%	47.61%	57.20%	-
Cost of Revenue to Revenue	15.33%	15.40%	16.08%	16.80%	16.49%	19.73%
SG&A Expenses to Revenue	23.20%	26.52%	28.64%	29.16%	29.06%	29.35%
R&D to Revenue	16.55%	13.97%	13.59%	12.62%	12.18%	11.65%
Operating Expenses to Revenue	40.48%	40.44%	41.65%	41.55%	40.87%	40.50%
Earnings before Interest and Taxes (EBIT)	17,813	15,221	10,762	8,925	8,897	7,886
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	20,466	16,618	11,821	9,842	9,842	8,736
Valuation Ratios	-	-	-	-	-	-
Price to Book Value (P/BV)	19.48	29.18	12,547,067.02	11,562,076.90	0.00	0.00
Price to Tangible Book Value (P/TBV)	86.28	67.38	32,184,362.22	29,663,488.40	0.00	0.00
Price to Revenue (P/Rev)	9.62	13.39	5,919,642.60	5,809,450.94	0.00	0.00
Price to Earnings (P/E)	27.68	37.16	18,865,455.88	17,127,765.41	0.00	0.00
Dividend Yield	1.68%	0.00%	1.21%	1.37%	1.97%	2.29%
Earnings Yield	3.61%	2.69%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	53.42	381.76	12,274,627.82	10,274,981.41	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	9.98	13.50	5,919,642.75	5,809,451.14	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	19.66	27.99	12,747,860.72	12,648,575.36	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	22.59	30.56	14,002,385.59	13,948,071.75	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	28.45	38.22	17,416,168.46	17,255,105.62	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	18.29	25.54	13,278,543.53	13,548,618.09	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	51.39	20.03	17,745,057.43	30,638,061.71	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-
Debt to Equity	0.77	0.27	0.34	0.41	0.19	0.00
Long-Term Debt to Equity	0.63	0.19	0.29	0.18	0.05	0.00
Financial Leverage	-0.76	-0.52	0.07	0.00	-0.14	0.00
Leverage Ratio	3.12	2.92	2.82	2.52	2.29	0.00
Compound Leverage Factor	3.09	2.98	2.61	2.54	2.25	0.00
Debt to Total Capital	43.47%	20.97%	25.57%	28.95%	15.62%	0.00%
Short-Term Debt to Total Capital	8.13%	5.75%	3.89%	15.94%	11.76%	0.00%
Long-Term Debt to Total Capital	35.33%	15.22%	21.68%	13.02%	3.86%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	56.53%	79.03%	74.43%	71.05%	86.81%	0.00%
Debt to EBITDA	0.75	0.25	0.35	0.45	0.20	0.00
Net Debt to EBITDA	0.71	0.22	0.32	0.42	-0.06	0.00
Long-Term Debt to EBITDA	0.61	0.18	0.30	0.20	0.05	0.00
Debt to NOPAT	1.08	0.34	0.48	0.61	0.27	0.00
Net Debt to NOPAT	1.02	0.30	0.43	0.57	-0.08	0.00
Long-Term Debt to NOPAT	0.88	0.25	0.40	0.27	0.07	0.00
Altman Z-Score	7.02	11.14	3,983,640.87	3,965,536.12	0.00	0.00
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	-1.41%	-2.88%	0.00%
Liquidity Ratios	-	-	-	-	-	-
Current Ratio	0.74	0.82	0.89	0.86	0.94	0.00
Quick Ratio	0.36	0.40	0.44	0.43	0.61	0.00
Cash Flow Metrics	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	7,830	23,227	8,492	4,063	-1,909	0.00
Operating Cash Flow to CapEx	336.06%	475.68%	534.72%	953.01%	235.35%	623.84%
Free Cash Flow to Firm to Interest Expense	7.68	185.23	9.86	10.89	-4.43	0.00
Operating Cash Flow to Interest Expense	21.58	145.27	13.18	24.63	19.80	0.00
Operating Cash Flow Less CapEx to Interest Expense	15.16	114.73	10.71	22.05	11.39	0.00
Efficiency Ratios	-	-	-	-	-	-
Asset Turnover	0.72	0.85	0.79	0.80	0.88	0.00
Accounts Receivable Turnover	4.11	4.08	3.78	3.99	4.58	0.00
Inventory Turnover	1.19	1.29	1.26	1.19	1.13	0.00
Fixed Asset Turnover	0.00	0.00	2.83	2.57	2.53	0.00
Accounts Payable Turnover	1.58	1.76	2.28	3.15	3.66	0.00
Days Sales Outstanding (DSO)	88.73	89.41	96.49	91.50	79.74	0.00
Days Inventory Outstanding (DIO)	306.85	282.96	289.63	305.78	323.22	0.00
Days Payable Outstanding (DPO)	230.46	207.77	160.20	116.05	99.69	0.00
Cash Conversion Cycle (CCC)	165.13	164.60	225.92	281.23	303.27	0.00
Capital & Investment Metrics	-	-	-	-	-	-
Invested Capital	7,532	1,218	12,277	12,116	8,965	0.00
Invested Capital Turnover	9.21	5.11	2.09	2.03	4.66	0.00
Increase / (Decrease) in Invested Capital	6,314	-11,058	160	3,152	8,965	0.00
Enterprise Value (EV)	402,384	465,156	150,689,711,919	124,493,291,098	0.00	0.00
Market Capitalization	387,950	461,494	150,689,708,184	124,493,286,967	0.00	0.00
Book Value per Share	$4.42	$0.00	$0.00	$4.66	$0.00	$0.00
Tangible Book Value per Share	$1.00	$0.00	$0.00	$1.82	$0.00	$0.00
Total Capital	35,228	20,009	16,137	15,155	12,335	0.00
Total Debt	15,312	4,196	4,127	4,388	1,927	0.00
Total Long-Term Debt	12,447	3,046	3,498	1,973	476	0.00
Net Debt	14,434	3,663	3,734	4,130	-554	0.00
Capital Expenditures (CapEx)	6,546	3,829	2,122	964	3,628	1,341
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-5,873	-3,651	-1,597	39	-1,764	0.00
Debt-free Net Working Capital (DFNWC)	-4,995	-3,303	-1,205	296	717	0.00
Net Working Capital (NWC)	-7,860	-4,453	-1,834	-2,119	-734	0.00
Net Nonoperating Expense (NNE)	127	-249	665	-54	130	474
Net Nonoperating Obligations (NNO)	-12,384	-14,595	267	1,349	-1,444	0.00
Total Depreciation and Amortization (D&A)	2,652	1,397	1,059	917	946	851
Debt-free, Cash-free Net Working Capital to Revenue	-14.57%	-10.59%	-6.28%	0.18%	-8.45%	0.00%
Debt-free Net Working Capital to Revenue	-12.39%	-9.58%	-4.73%	1.38%	3.43%	0.00%
Net Working Capital to Revenue	-19.50%	-12.92%	-7.20%	-9.89%	-3.52%	0.00%
Earnings Adjustments	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$3.15	$18.67	$12.26	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic Shares Outstanding	4.47B	4.51B	4560T	0.00	0.00	0.00
Adjusted Diluted Earnings per Share	$3.14	$18.62	$12.22	$0.00	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	4.47B	4.51B	4560T	0.00	0.00	0.00
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	4.47B	4.51B	4560T	0.00	0.00	0.00
Normalized Net Operating Profit after Tax (NOPAT)	14,144	12,169	8,652	7,215	7,056	6,326
Normalized NOPAT Margin	35.09%	35.31%	33.99%	33.67%	33.82%	34.49%
Pre Tax Income Margin	43.80%	45.07%	39.03%	41.96%	41.85%	39.77%
Debt Service Ratios	-	-	-	-	-	-
EBIT to Interest Expense	17.47	121.39	12.50	23.93	20.63	0.00
NOPAT to Interest Expense	13.87	97.05	10.05	19.34	16.36	0.00
EBIT Less CapEx to Interest Expense	11.05	90.85	10.03	21.34	12.21	0.00
NOPAT Less CapEx to Interest Expense	7.45	66.51	7.58	16.76	7.95	0.00
Payout Ratios	-	-	-	-	-	-
Dividend Payout Ratio	43.71%	37.96%	45.57%	45.06%	47.75%	49.83%
Augmented Payout Ratio	63.69%	73.72%	88.95%	85.78%	87.75%	89.20%

No quarterly metrics and ratios for Novo Nordisk A/S are available.

Frequently Asked Questions About Novo Nordisk A/S's Financials

When does Novo Nordisk A/S's financial year end?

According to the most recent income statement we have on file, Novo Nordisk A/S's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Novo Nordisk A/S's net income changed over the last 5 years?

Novo Nordisk A/S's net income appears to be on an upward trend, with a most recent value of $14.02 billion in 2024, rising from $5.85 billion in 2019. The previous period was $12.42 billion in 2023. Check out Novo Nordisk A/S's forecast to explore projected trends and price targets.

What is Novo Nordisk A/S's operating income?

Novo Nordisk A/S's total operating income in 2024 was $17.81 billion, based on the following breakdown:

Total Gross Profit: $34.13 billion
Total Operating Expenses: $16.31 billion

How has Novo Nordisk A/S revenue changed over the last 5 years?

Over the last 5 years, Novo Nordisk A/S's total revenue changed from $18.34 billion in 2019 to $40.31 billion in 2024, a change of 119.7%.

How much debt does Novo Nordisk A/S have?

Novo Nordisk A/S's total liabilities were at $44.74 billion at the end of 2024, a 45.0% increase from 2023, and a 233.6% increase since 2020.

How has Novo Nordisk A/S's book value per share changed over the last 5 years?

Over the last 5 years, Novo Nordisk A/S's book value per share changed from 0.00 in 2019 to 4.42 in 2024, a change of 441.6%.

Related Companies

This page (NYSE:NVO) was last updated on 5/28/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Novo Nordisk A/S (NVO) Financials

Frequently Asked Questions About Novo Nordisk A/S's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Novo Nordisk A/S (NVO) Financials

Annual Income Statements for Novo Nordisk A/S

Quarterly Income Statements for Novo Nordisk A/S

Annual Cash Flow Statements for Novo Nordisk A/S

Quarterly Cash Flow Statements for Novo Nordisk A/S

Annual Balance Sheets for Novo Nordisk A/S

Quarterly Balance Sheets for Novo Nordisk A/S

Annual Metrics And Ratios for Novo Nordisk A/S

Quarterly Metrics And Ratios for Novo Nordisk A/S

Frequently Asked Questions About Novo Nordisk A/S's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools